[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna, M
[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis]. [electronic resource] - Reumatismo - 163-71 p. digital
Publication Type: English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
0048-7449
10.4081/reumatismo.2010.163 doi
Alendronate--adverse effects
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Bone Remodeling--drug effects
Clinical Trials as Topic--statistics & numerical data
Denosumab
Drug Delivery Systems
Female
Fracture Healing--drug effects
Fractures, Spontaneous--etiology
Humans
Immunosuppressive Agents--administration & dosage
Injections, Subcutaneous
Models, Biological
Multicenter Studies as Topic--statistics & numerical data
Osteoclasts--drug effects
Osteonecrosis--chemically induced
Osteoporosis, Postmenopausal--complications
Patient Compliance
RANK Ligand--administration & dosage
Receptor Activator of Nuclear Factor-kappa B--physiology
[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis]. [electronic resource] - Reumatismo - 163-71 p. digital
Publication Type: English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
0048-7449
10.4081/reumatismo.2010.163 doi
Alendronate--adverse effects
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Bone Remodeling--drug effects
Clinical Trials as Topic--statistics & numerical data
Denosumab
Drug Delivery Systems
Female
Fracture Healing--drug effects
Fractures, Spontaneous--etiology
Humans
Immunosuppressive Agents--administration & dosage
Injections, Subcutaneous
Models, Biological
Multicenter Studies as Topic--statistics & numerical data
Osteoclasts--drug effects
Osteonecrosis--chemically induced
Osteoporosis, Postmenopausal--complications
Patient Compliance
RANK Ligand--administration & dosage
Receptor Activator of Nuclear Factor-kappa B--physiology